C.M., Pannuti C., Chehter L., Mayer M.P., Lima L.A., Persistence of Helicobacter pylori in the oral cavity after systemic eradication therapy, J. Clin. Periodontol., 2006, 33, 329-333. 10.1111/j.1600-051X.2006.00915.x Gebara E.C. Faria C.M. Pannuti C. Chehter L. Mayer M.P. Lima L.A. Persistence of Helicobacter pylori in the oral cavity after systemic eradication therapy J. Clin. Periodontol. 2006 33 329 333
 Forman D., Newell D.G., Fullerton F., Yarnell JW, Stacey AR, Wald N, et al., Association between infection with Helicobacter pylori and risk gastric
al., ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells, Mol. Carcinog., 2016, 55(1), 27-39. 10.1002/mc.22255 Holl M. Koziel R. Schäfer G. Pircher H. Pauck A. Hermann M. ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells Mol. Carcinog. 2016 55 1 27 39
 Sharpless N.E., Ramsey M.R., ROS as a tumour suppressor, News Views, 2006, 8, 1213-1215. Sharpless N.E. Ramsey M.R. ROS as a tumour suppressor News Views 2006 8 1213 1215
 Shan C., Elf S., Ji Q., Kang H
transformation of hepatocytes and its regulatory mechanism, Shi Jie Hua Ren Xiao Hua Za Zhi, 2015, 23(05), 741-747. Xia H. Zhu M.Y. Li M.S. The effect of HBx induced alpha fetoprotein expression on malignant transformation of hepatocytes and its regulatory mechanism Shi Jie Hua Ren Xiao Hua Za Zhi 2015 23 05 741 747
 Kotake Y., Naemura M., Murasaki C., Inoue Y., Okamoto H., Transcriptional regulation of the p16 tumor suppressor gene, Anticancer Res., 2015, 35(8), 4397-4401. Kotake Y. Naemura M. Murasaki C. Inoue Y. Okamoto H. Transcriptional regulation of the p16 tumor
pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review, Int. J. Antimicrob. Agents, 2013, 42(4), 289-293. 10.1016/j.ijantimicag.2013.05.018 Parker S. Lipman J. Koulenti D. Dimopoulos G. Roberts J.A. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review Int. J. Antimicrob. Agents 2013 42 4 289 293
 Gattringer R., Meyer B., Heinz G., Guttmann C., Zeitlinger M., Joukhadar C., Single-dose pharmacokinetics of fosfomycin during continuous
statistics in the year 2000. Lancet Oncol 2001; 2:533–543. 10.1016/S1470-2045(01)00486-7 Parkin DM. Global cancer statistics in the year 2000 Lancet Oncol 2001 2 533 543
 Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15:5–13. 10.1634/theoncologist.2010-S4-05 Venook AP. Papandreou C. Furuse J. de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective Oncologist 2010 15 5 13
 Cancer IARC. Globocan
1 Lee WM. Hepatitis B virus infection. N Engl J Med,1997,337(24):1733-1745.
2 Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology, 2009, 49 (5Suppl): S138-145.
3 Kourtis AP, Bulterys M, Hu DJ, et al . HIV-HBV coinfection a global challenge. N Engl J Med, 2012, 366(19): 1749-1752.
4 Wang H, Li Y, Zhang C, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS, 2012, 26(14): 1755-1763.
5 Colin JF, Cazals-Hatem D, Loriot MA, et al
Zhi-Jian Li, Xing-Ling Sui, Xue-Bo Yang and Wen Sun
corresponding BMs and PB, respectively. The comparison among the number of DEGs obtained in the four experiments showed that LB cells did not tend to differentiation and CD34+ was more similar to cancer stem cells. The heatmaps of the top 20 DEGs obtained in the four experiments are shown in Figures 2 – 5 , respectively. As shown in Figure 2 , the top 5 ranked DEGs in experiment 1 were GYPA, LCK, ITK, BCL11B, and RHAG. In Figure 3 , the top 5 ranked DEGs were TAL1, RHOH, MYH10, TYROBP, and CFD. In Figure 4 , the top 5 ranked DEGs were CXCR2, MGAM, TNFRSF10C, KCNJ15, and